Insulin in Total Parenteral Nutrition (INSUPAR)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02706119 |
|
Recruitment Status :
Completed
First Posted : March 11, 2016
Last Update Posted : May 24, 2018
|
Sponsor:
Fundación Pública Andaluza Progreso y Salud
Information provided by (Responsible Party):
Andalusian Network for Design and Translation of Advanced Therapies ( Fundación Pública Andaluza Progreso y Salud )
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
Analyze the level of metabolic control achieved with a routine of regular insulin in the parenteral nutrition (PN) reservoir in addition to subcutaneous glargine insulin, versus only regular insulin in the PN reservoir.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Diabetes Mellitus | Drug: Subcutaneous glargine insulin Drug: Regular insulin added to TPN bag | Phase 4 |
A pattern of basal insulin (using subcutaneous insulin glargine and regulating the stock as prandial), plus regular subcutaneous insulin as rescue, applied to total parenteral nutrition (TPN) should be as effective (glycemic control, variability) and safe (hypoglycemia) as the usual (regular insulin inside the TPN reservoir and subcutaneous insulin as rescue) in patients with type 2 diabetes critics.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 163 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Screening |
| Official Title: | Subcutaneous Versus Intravenous Basal Insulin in Non-critical Hospitalized Diabetic Patients That Receive Total Parenteral Nutrition |
| Actual Study Start Date : | July 1, 2016 |
| Actual Primary Completion Date : | March 31, 2018 |
| Actual Study Completion Date : | April 4, 2018 |
Resource links provided by the National Library of Medicine
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Glargine insulin
Single dose glargine insulin (basal component) + regular insulin within total parenteral nutrition (TPN) reservoir (prandial component). 50% of the total calculated dose of insulin is administered subcutaneously as single dose subcutaneous glargine insulin; remaining 50% of the total calculated dose of insulin is administered as regular insulin in the TPN reservoir. Interventions used: Intravenous glargine insulin, and regular insulin added to TPN bag
|
Drug: Subcutaneous glargine insulin
Glargine insuline is an insulin analogue which has a prolonged duration of action. Insulin glargine is obtained by recombinant DNA technology in Escherichia coli.
Other Names:
Drug: Regular insulin added to TPN bag Regular insulin is human insulin produced in Saccharomyces cerevisiae by recombinant DNA technology.
Other Names:
|
|
Active Comparator: Regular insulin
Regular insulin added to TPN bag (basal + prandial component). The calculated total dose of insulin is administered as regular insulin in the TPN reservoir. Interventions used: Regular insulin added to TPN bag
|
Drug: Regular insulin added to TPN bag
Regular insulin is human insulin produced in Saccharomyces cerevisiae by recombinant DNA technology.
Other Names:
|
Primary Outcome Measures :
- Basal blood glucose value before starting TPN [ Time Frame: Before starting total parenteral nutrition ]Basal glucose value before starting TPN (in mg/dL).
- Periodical blood glucose [ Time Frame: Every 6h during 15 days of treatment ]All blood glucose values (in mg/dL) every 6 hours during 15 days of TPN infusion.
- Variation of average blood glucose compared with total dose of insulin [ Time Frame: In days 1, 5 and 15 of treatment ]Variation of average glucose (in mg/dL) compared with total dose of insulin (in mL), in days 1, 5 and 15 of treatment.
- Number of hypoglycaemia [ Time Frame: During TPN treatment up to 15 days ]Number of symptomatic and asymptomatic hypoglycaemia with blood glucose below 70 mg/dL during TPN treatment up to 15 days.
- Number of severe hypoglycaemia [ Time Frame: During TPN treatment up to 15 days ]Number of symptomatic and asymptomatic hypoglycaemia with blood glucose below 40 mg/dL during TPN treatment up to 15 days.
- Hypoglycemia blood glucose values [ Time Frame: Through study completion, an average of 15 days. ]If the patient refers typical symptoms of hypoglycemia, a measure of blood glucose (in mg/mL) is immediately taken to check the level
- Hypoglycemia symptoms [ Time Frame: Through study completion, an average of 15 days. ]If blood glucose <70 mg / dL, it is recorded whether or not the patient has symptoms consistent with hypoglycemia and how the episode terminates
Secondary Outcome Measures :
- Standard deviation of blood glucose [ Time Frame: At day 15 of treatment ]Standard deviation of blood glucose (SD): Expressed in milligrams per deciliter (in mg/dL).
- Blood glucose coefficient of variation (CV) [ Time Frame: At day 15 of treatment ]Coefficient of variation (CV): Expressed as a percentage (%). The ratio of the standard deviation of the blood glucoses values (in mg/dL) and the average blood glucose (in mg/dL), multiplied by 100.
Other Outcome Measures:
- Infections related with catheter used in parenteral nutrition [ Time Frame: At day 15 of treatment ]Investigator asses the occurrence of infectious complications in parenteral nutrition catheter. For the evaluation of the infections, temperature is collected daily and patient will perform a blood test weekly. It will be suspected infectious complication for any sudden onset of fever (usually "peaks"), with no other apparent source of infection.
- Hypertriglyceridemia [ Time Frame: Every 6h during 15 days of treatment. ]A determination above this value will be considered a complication: Hypertriglyceridemia ≥500 mg/dL
- Hypernatremia [ Time Frame: Every 6h during 15 days of treatment. ]A determination above this value will be considered a complication: Hypernatremia >150 mEq/L
- Hyponatremia [ Time Frame: Every 6h during 15 days of treatment. ]A determination below this value will be considered a complication: Hyponatremia <135 mEq/L
- Hypokalemia [ Time Frame: Every 6h during 15 days of treatment. ]A determination below this value will be considered a complication: Hypokalemia <3 mEq/L
- Hypomagnesemia [ Time Frame: Every 6h during 15 days of treatment. ]A determination below this value will be considered a complication: Hypomagnesemia <1.2 mg/dL
- Hypophosphatemia [ Time Frame: Every 6h during 15 days of treatment. ]A determination below this value will be considered a complication: Hypophosphatemia <2 mg/dL
- Hyperchloremia [ Time Frame: Every 6h during 15 days of treatment. ]A determination above this value will be considered a complication: Hyperchloremia >120 mEq/L
- Hypocalcemia corrected calcium [ Time Frame: Every 6h during 15 days of treatment. ]A determination below this value will be considered a complication: Hypocalcemia corrected calcium <8 mg/dL
- Alteration of liver function markers [ Time Frame: At day 7 and 15 of treatment ]Alteration of liver function markers is defined as an elevation twice higher than normal limits, according to each laboratory, of two of some of the following parameters (when previously normal): GGT, GOT, GPT, FA or total bilirubin, at least 7 days after initiating TPN.
- Adverse events [ Time Frame: At day 15 of treatment ]All adverse events (AEs) are recorded in the case report data since the moment when the patient signs the informed consent. These events will be defined following the organ classification database of MedDRA system.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Adults (>18 years)
- Previously diagnosed with diabetes mellitus.
- Hospitalized but without intensive cares.
- Have indication of total parenteral nutritional support (TPN, meaning the covering over 70% of the estimated daily requirements intravenously) for a minimum of 5 days.
- Signature of informed consent.
Exclusion Criteria:
- Diabetes mellitus type 1, diabetes secondary to total pancreatectomy.
- Patients with intensive cares.
- Patients who have been prescribed TPN in intensive cares unity more than 48 hours before admission to hospitalization.
- Intradialytic parenteral nutrition.
- Patients under 18 or pregnant women.
- Patients with renal insufficiency stage 3 B (glomerular filtration rate < 45 mL / min).
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02706119
Locations
Show 32 study locations
Sponsors and Collaborators
Fundación Pública Andaluza Progreso y Salud
Investigators
| Principal Investigator: | Gabriel Olveira Fuster, PhD | Hospital Regional de Malaga |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Fundación Pública Andaluza Progreso y Salud |
| ClinicalTrials.gov Identifier: | NCT02706119 |
| Other Study ID Numbers: |
FPS-INSUPAR-2015-01 |
| First Posted: | March 11, 2016 Key Record Dates |
| Last Update Posted: | May 24, 2018 |
| Last Verified: | April 2018 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
Keywords provided by Andalusian Network for Design and Translation of Advanced Therapies ( Fundación Pública Andaluza Progreso y Salud ):
|
total parenteral nutrition glargine insulin insulin |
Additional relevant MeSH terms:
|
Insulin Insulin, Globin Zinc Insulin Glargine Hypoglycemic Agents Physiological Effects of Drugs |